CN119708144A - 肽化合物及其治疗疾病的方法 - Google Patents
肽化合物及其治疗疾病的方法 Download PDFInfo
- Publication number
- CN119708144A CN119708144A CN202411888874.5A CN202411888874A CN119708144A CN 119708144 A CN119708144 A CN 119708144A CN 202411888874 A CN202411888874 A CN 202411888874A CN 119708144 A CN119708144 A CN 119708144A
- Authority
- CN
- China
- Prior art keywords
- peptide
- peptides
- disease
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL272074A IL272074B2 (en) | 2020-01-15 | 2020-01-15 | Peptide compounds and methods of treating diseases using same |
| IL272074 | 2020-01-15 | ||
| CN202180017719.4A CN115942948B (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| PCT/IL2021/050044 WO2021144798A1 (en) | 2020-01-15 | 2021-01-14 | Peptide compounds and methods of treating diseases using same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180017719.4A Division CN115942948B (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119708144A true CN119708144A (zh) | 2025-03-28 |
Family
ID=76863930
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411888874.5A Pending CN119708144A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888865.6A Pending CN119708140A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888870.7A Pending CN119708142A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888869.4A Pending CN119708141A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888873.0A Pending CN119708143A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202180017719.4A Active CN115942948B (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411888865.6A Pending CN119708140A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888870.7A Pending CN119708142A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888869.4A Pending CN119708141A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202411888873.0A Pending CN119708143A (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
| CN202180017719.4A Active CN115942948B (zh) | 2020-01-15 | 2021-01-14 | 肽化合物及其治疗疾病的方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230049549A1 (enExample) |
| EP (1) | EP4090347A1 (enExample) |
| JP (1) | JP7809060B2 (enExample) |
| KR (1) | KR20220145826A (enExample) |
| CN (6) | CN119708144A (enExample) |
| AU (1) | AU2021207415A1 (enExample) |
| BR (1) | BR112022013978A2 (enExample) |
| CA (1) | CA3167139A1 (enExample) |
| CO (1) | CO2022011101A2 (enExample) |
| IL (1) | IL272074B2 (enExample) |
| MX (1) | MX2022008746A (enExample) |
| WO (1) | WO2021144798A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280101B2 (en) | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| WO2003037172A2 (en) * | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| AU2005276117C1 (en) * | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| US8648045B2 (en) * | 2005-03-10 | 2014-02-11 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | VDAC1 compositions and methods of use thereof for regulating apoptosis |
| CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| US20130096070A1 (en) * | 2009-04-07 | 2013-04-18 | University Of Kansas | Peptide targeting of inner ear cells |
| CA2836503C (en) * | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| IL280101B2 (en) * | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
-
2020
- 2020-01-15 IL IL272074A patent/IL272074B2/en unknown
-
2021
- 2021-01-14 US US17/792,787 patent/US20230049549A1/en active Pending
- 2021-01-14 EP EP21704023.7A patent/EP4090347A1/en active Pending
- 2021-01-14 CN CN202411888874.5A patent/CN119708144A/zh active Pending
- 2021-01-14 KR KR1020227028077A patent/KR20220145826A/ko active Pending
- 2021-01-14 JP JP2022542986A patent/JP7809060B2/ja active Active
- 2021-01-14 CN CN202411888865.6A patent/CN119708140A/zh active Pending
- 2021-01-14 CN CN202411888870.7A patent/CN119708142A/zh active Pending
- 2021-01-14 CN CN202411888869.4A patent/CN119708141A/zh active Pending
- 2021-01-14 CA CA3167139A patent/CA3167139A1/en active Pending
- 2021-01-14 CN CN202411888873.0A patent/CN119708143A/zh active Pending
- 2021-01-14 CN CN202180017719.4A patent/CN115942948B/zh active Active
- 2021-01-14 AU AU2021207415A patent/AU2021207415A1/en active Pending
- 2021-01-14 MX MX2022008746A patent/MX2022008746A/es unknown
- 2021-01-14 BR BR112022013978A patent/BR112022013978A2/pt unknown
- 2021-01-14 WO PCT/IL2021/050044 patent/WO2021144798A1/en not_active Ceased
-
2022
- 2022-08-04 CO CONC2022/0011101A patent/CO2022011101A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022008746A (es) | 2022-10-13 |
| WO2021144798A1 (en) | 2021-07-22 |
| CN119708141A (zh) | 2025-03-28 |
| JP7809060B2 (ja) | 2026-01-30 |
| CN115942948A (zh) | 2023-04-07 |
| CA3167139A1 (en) | 2021-07-22 |
| EP4090347A1 (en) | 2022-11-23 |
| US20230049549A1 (en) | 2023-02-16 |
| CN119708142A (zh) | 2025-03-28 |
| CO2022011101A2 (es) | 2022-11-08 |
| AU2021207415A1 (en) | 2022-09-08 |
| JP2023510019A (ja) | 2023-03-10 |
| IL272074B2 (en) | 2024-12-01 |
| CN119708143A (zh) | 2025-03-28 |
| IL272074A (en) | 2021-07-29 |
| CN115942948B (zh) | 2025-01-14 |
| BR112022013978A2 (pt) | 2022-10-11 |
| CN119708140A (zh) | 2025-03-28 |
| KR20220145826A (ko) | 2022-10-31 |
| IL272074B1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7682248B2 (ja) | ペプチド化合物およびその治療的用途 | |
| CN115942948B (zh) | 肽化合物及其治疗疾病的方法 | |
| JP2004516301A (ja) | 癌治療のためのｅ２ｆ−１／サイクリン相互作用の阻害剤 | |
| EP2578226B1 (en) | Peptide for treating amyotrophic lateral sclerosis | |
| RU2812775C2 (ru) | Пептидные соединения и их терапевтическое применение | |
| RU2843553C2 (ru) | Пептидные соединения и их терапевтическое применение | |
| EA044784B1 (ru) | Пептидные соединения и способы лечения заболеваний с их использованием | |
| EA046208B1 (ru) | Пептидные соединения и их терапевтическое применение | |
| EA051325B1 (ru) | Пептидные соединения и их терапевтическое применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |